Cargando…

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

DNA-dependent protein kinase (DNA-PK) has been shown to play a crucial role in repair of DNA double-strand breaks, facilitating nonhomologous end-joining. DNA-PK inhibitors have the potential to block DNA repair and therefore enhance DNA-damaging agents. M3814 is a DNA-PK inhibitor that has shown pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wise, Hannah C., Iyer, Gopakumar V., Moore, Kathleen, Temkin, Sarah M., Gordon, Sarah, Aghajanian, Carol, Grisham, Rachel N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906487/ https://www.ncbi.nlm.nih.gov/pubmed/31827119 http://dx.doi.org/10.1038/s41598-019-54796-6

Ejemplares similares

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
por: Gordhandas, Sushmita B., et al.
Publicado: (2022)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
por: Carr, Michael I., et al.
Publicado: (2020)

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
por: Wang, Manni, et al.
Publicado: (2021)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
por: van Bussel, Mark T. J., et al.
Publicado: (2020)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV
por: Kokot, Maja, et al.
Publicado: (2022)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
por: Gerrits, C. J., et al.
Publicado: (1997)

Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates
por: Han, Seungmin, et al.
Publicado: (2022)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

In Vitro Activity of Novel Topoisomerase Inhibitors against Francisella tularensis and Burkholderia pseudomallei
por: Whelan, Adam O., et al.
Publicado: (2023)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
por: Musk, S. R., et al.
Publicado: (1990)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality
por: Yakovlev, Vasily A., et al.
Publicado: (2023)

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
por: Davidson, David, et al.
Publicado: (2013)

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation()
por: Martin, Madhuri, et al.
Publicado: (2017)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors
por: Haeger, Sarah M., et al.
Publicado: (2015)

Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
por: Lal, Shruti, et al.
Publicado: (2023)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV‐1 infection of macrophages
por: Mlcochova, Petra, et al.
Publicado: (2017)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
por: Jong, R S de, et al.
Publicado: (1999)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
por: Huang, Hsien-Sung, et al.
Publicado: (2011)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes
por: Chae, Sieun, et al.
Publicado: (2018)

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
por: McKenzie, Jodi A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0jlfgnjpq2194c199sbnblguhc